Drugs / [18F]MNI-946
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03071224 | Jun 2016 → Jun 2021 | Alzheimer disease | Invicro | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]MNI-946 | “The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.” NCT03071224 ↗ |
| Known as | [18F]MK-6240 | “The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.” NCT03071224 ↗ |
| Modality | Diagnostic / imaging agent | “Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.” NCT03071224 ↗ |